Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy

Cancer Journal from Scientific American

Volumn 5, Issue 5, 1999, Pages 301-306

  Potters, Louis ^a   Cha, Christine ^b   Oshinsky, Gary ^c   Venkatraman, Ennapadam ^a   Zelefsky, Michael ^a   Leibel, Steven ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b VIRGINIA MASON MEDICAL CENTER   (United States)

^c Mercy Medical Center   (United States)

Author keywords

Brachytherapy; Iodine; Palladium; Prostate cancer; Radiotherapy

Indexed keywords

IODINE 125; PALLADIUM; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BEAM THERAPY; BRACHYTHERAPY; CANCER SURVIVAL; HUMAN; INTERSTITIAL RADIATION; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADIATION DOSE; REGRESSION ANALYSIS; RISK ASSESSMENT;

ADENOCARCINOMA; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; HUMANS; IODINE RADIOISOTOPES; MALE; PALLADIUM; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOISOTOPES; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0032842843     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Blasko JC, Ragde H, Grimm PD. Transperineal ultrasound-guided implantation of the prostate: morbidity and complications. Scand J Urol Nephrol Suppl. 1991;137:113-118.
2. Mate TP, Gottesman JE, Hatton J et al. High dose-rate afterloading 192 iridium prostate brachytherapy: feasibility report. Im J Radiat Oncol Biol Phys 1998;41:525-33.
3. Leibel SA, Kutcher GJ, Zelefsky MJ et al. 3-D conformal radiotherapy for carcinoma of the prostate: clinical experience at the Memorial Sloan-Kettering Cancer Center. Front Radiat Ther Oncol 1996; 29:229-237.
4. Buder EB, Scardino PT, Teh BS et al. The Baylor College of Medicine experience with gold seed implantation. Semin Surg Oncol 1997;13:406-418.
5. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 1997;37:1035-1041.
6. Pound CR, Partin AW, Epstein JI et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy: patterns of recurrence and cancer control. Urol Clin North Am 1997;24:395-406.
7. Lerner SE, Blute ML, Bergstralh EJ et al. Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J Urol 1996;156:137-143.
8. Pisansky TM, Cha SS, Earle JD et al. Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol 1993;11: 2158-2166.
9. Kupelian P, Katcher J, Levin H et al. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores. Cancer J Sci Am 1997;3:78-87.
10. Zelefsky MJ, Leibel SA, Gaudin PB et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998;41:491-500.
11. Bauer JJ, Connelly RR, Seterhenn IA et al. Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer. J Urol 1998;159:929-933.
12. D'Amico AV, Desjardin A, Chen MH et al. Analyzing outcome-based staging for clinically localized adenocarcinoma of the prostate. Cancer 1998;83:2172-2180.
13. Fleming ID, Cooper JS, Henson DE et al. AJCC Cancer Staging Manual, (5th ed) Philadelphia: Lippincott-Raven, 1997.
14. Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep 1966;50:125-128.
15. Nath R, Anderson LL, Meli JA et al. Code of practice for brachytherapy physics: report of the AAPM Radiation Therapy Committee Task Group No. 56. American Association of Physicists in Medicine. Med Phys 1997;24:1557-1598.
16. Anderson LL, Moni JV, Harrison LB. A nomograph for permanent implants of palladium-103 seeds. Int J Radiat Oncol Biol Phys 1993; 27:129-135.
17. Dattoli M, Wallner K, Sorace R et al. 103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma. Im J Radiat Oncol Biol Phys 1996;35:875-879.
18. Unger PD, Hoon V, Stone N et al. Computerized interactive morphometry in the diferrential diagnosis of irradiated prostates. Anal Quant Cytol Histol 1995;17:100-108.
19. Cox DR, Abadir R. Regression models and life tables. J Roy Statist Soc 1972;34:187-220.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Cancer Res Clin Oncol 1958;53:457-816.
21. Grado GL, Larson TR, Balch CS et al. Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance. Im J Radiat Oncol Biol Phys 1998;42:289-298.
22. Critz FA, Tarlton RS, Holladay DA Prostate specific antigen-monitored combination radiotherapy for patients with prostate cancer: 1-125 implant followed by external-beam radiation. Cancer 1995;75: 2383-2391.
23. Ragde H, Blasko JC, Grimm PD et al. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer 1997;80:442-453.
24. Lattanzi JP, Hanlon AL, Hanks GE. Early stage prostate cancer treated with radiation therapy: stratifying an intermediate risk group. Im J Radiat Oncol Biol Phys 1997;38:569-573.
25. Beyer DC, Priestley JBJ. Biochemical disease-free survival following 1251 prostate implantation. Int J Radiat Oncol Biol Phys 1997;37: 559-563.
26. Zelefsky MJ, Leibel SA, Kutcher GJ et al. Three-dimensional conformal radiotherapy and dose escalation: where do we stand? Semin Radiat Oncol 1998;8:107-114.
27. Zelefsky MJ, Wallner KE, Ling CC et al. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol 1999;17:517-522.
28. Ragde H, Elgamal AA, Snow PB et al. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer 1998;83:989-1001.
29. D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-974.
30. Critz FA, Levinson AK, Williams WH et al. Prostate-specific antigen nadir: the optimum level after irradiation for prostate cancer. J Clin Oncol 1996;14:2893-2900.
31. Zelefsky MJ, Leibel SA, Wallner KE et al. Significance of normal serum prostate-specific antigen in the follow-up period after definitive radiation therapy for prostatic cancer. J Clin Oncol 1995;13:459-463.